ENTO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Entero Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.51 |
52 Week High | US$9.35 |
52 Week Low | US$0.18 |
Beta | 0.97 |
1 Month Change | -4.74% |
3 Month Change | 16.78% |
1 Year Change | -90.16% |
3 Year Change | -99.99% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02Shareholder Returns
ENTO | US Biotechs | US Market | |
---|---|---|---|
7D | -6.5% | 0.4% | 1.5% |
1Y | -90.2% | -2.7% | 22.4% |
Return vs Industry: ENTO underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ENTO underperformed the US Market which returned 22.4% over the past year.
Price Volatility
ENTO volatility | |
---|---|
ENTO Average Weekly Movement | 17.1% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 18.0% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENTO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENTO's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 9 | James Sapirstein | www.enterothera.com |
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
Entero Therapeutics, Inc. Fundamentals Summary
ENTO fundamental statistics | |
---|---|
Market cap | US$2.45m |
Earnings (TTM) | -US$8.15m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs ENTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENTO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$8.15m |
Earnings | -US$8.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.71 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ENTO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/16 12:03 |
End of Day Share Price | 2025/02/14 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entero Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Argus Research Company |
Jonathan Aschoff | B. Riley Wealth |
Leland Gershell | Oppenheimer & Co. Inc. |